Treatment-resistant Depression (TRD) research hub
4 indexed studies · 1 currently recruiting
- recruitingPHASE2
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
This study is testing a new medicine called ALTO-207 for people with depression that hasn't improved with other treatments. Researchers want to see if ALTO-207 helps reduce symptoms more than a dummy pill.
United States · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression
This study is testing a new nasal spray, BPL-003, for people with depression that hasn't responded to other treatments. Researchers are looking at different doses to see how well it works and if it's safe.
Poland · Spain · Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in patients with treatment-resistant depression.
This study is looking into a new treatment, GH001, for people whose depression hasn't responded to usual treatments. It aims to see if GH001 is safe and helps improve mood, compared to a dummy treatment. Participants will also have the option to continue treatment after the main study.
Poland · Czechia · Germany - authorisedTherapeutic confirmatory (Phase III)
Dehydroepiandrosterone (DHEA) as augmentation of standard antidepressants in treatment-resistant depression: a randomized controlled trial (DARE-Trial) - A multicenter, randomized, double-blind, placebo-controlled trial with group sequential design
This study is testing a new tablet called DHEA alongside usual antidepressant treatment for people with depression that hasn't improved with other treatments. Researchers want to see if DHEA helps reduce depression symptoms over six weeks and if it's safe to use.
Germany